DF/HCC Program Affiliation

Neuro-Oncology

DF/HCC Associations

MGH, Neuro-Oncology, Clinical Trial Chairs

Research Abstract

My work involves 1) the development of experimental trials of novel agents for patients with glioblastoma and primary CNS lymphoma (PCNSL) and 2) the identification of molecular markers of prognosis in patients with malignant glioma. With respect to therapeutic studies, I am the Principal Investigator (PI) of the MGH U01 grant, New Approaches to Brain Tumor Therapy (NABTT). In this role I have served as the PI of several national, multicenter therapeutic trials (CPT-11 for recurrent glioblastoma; oxaliplatin for newly diagnosed glioblastoma; Methotrexate for newly diagnosed PCNSL; Methotrexate and thio-TEPA for newly diagnosed PCNSL; rituximab for relapsed PCNSL). I am also the PI of an R21-funded study of AZD2171, an oral VEGFR2 tyrosine kinase inhibitor, in patients with recurrent glioblastoma. The study includes correlative investigations of possible drug effects on circulating endothelial and progenitor cells; circulating cytokines and such magnetic resonance imaging (MRI) parameters as arterial spin labeling; perfusion-weighted imaging and diffusion-weighted imaging. Other approved and funded studies of molecularly-targeted drugs in glioblastoma that I lead include: MLN518; PTK787; ZD6474 and sunitinib.

My work on molecular markers of prognosis incorporates data from two major resources: a longitudinal, electronic patient research database and a large brain tumor bank. In our studies we have demonstrated that the prognostic effects of EGFR and TP53 in glioblastoma (survival, response to radiation) are a function of the age of the patient. We have also demonstrated that BCL-6 is a significant positive prognostic marker in patients with PCNSL. Current molecular prognosis studies focus on anaplastic oligoastrocytomas; anaplastic oligodendrogliomas and glioblastoma.

Publications

• Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, Iafrate AJ, Louis DN.Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomid
  17404084
• Norden AD, Batchelor TT.Reversible posterior leukoencephalopathy syndrome.Onkologie 2007 Mar;30(3):90-1.
  17341892
• Correa D, Maron L, Harder H, Klein M, Armstrong C, Calabrese P, Bromberg J, Abrey L, Batchelor T, Schiff D.Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines.Ann Oncol 2007 Feb 6.
  17284616
• Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK.AZD2171, a pan-VEGF receptor ty
  17222792
• Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, Nutt CL.Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival.J Neuropathol Exp Neurol 2006 Dec;65(12):1181-8.
  17146292
• Eichler AF, Batchelor TT.Primary central nervous system lymphoma: presentation, diagnosis and staging.Neurosurg Focus 2006;21(5):E15.
  17134117
• Batchelor TT, Byrne TN.Supportive care of brain tumor patients.Hematol Oncol Clin North Am 2006 Dec;20(6):1337-61.
  17113467
• Gerber DE, Grossman SA, Batchelor T, Ye X.Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma.Cancer Chemother Pharmacol 2007 Jun;59(6):817-23.
  16972068
• Grossman SA, Carson KA, Batchelor TT, Lesser G, Mikkelsen T, Alavi JB, Phuphanich S, Hammour T, Fisher JD, Supko JG.The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride.Clin Cancer Res 2006
  16951236
• Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, Greenman C, Edkins S, Bignell G, Davies H, O'Meara S, Parker A, Avis T, Barthorpe S, Brackenbury L, Buck G, Butler A, Clements J, Cole J, Dicks E, Forbes S, Gorton M, Gray K, Halliday K, Harri
  16618716
• Jahnke K, Korfel A, O'neill BP, Blay JY, Abrey LE, Martus P, Poortmans PM, Shenkier TN, Batchelor TT, Neuwelt EA, Raizer JJ, Schiff D, Pels H, Herrlinger U, Stein H, Thiel E.International study on low-grade primary central nervous system lymphoma.Ann Neur
  16586496
• Batchelor T, Loeffler JS.Primary CNS lymphoma.J Clin Oncol 2006 Mar 10;24(8):1281-8.
  16525183
• Shah GD, Kesari S, Xu R, Batchelor TT, O'Neill AM, Hochberg FH, Levy B, Bradshaw J, Wen PY.Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas.Neuro-oncol 2006 Jan;8(1):38-46.
  16443946
• Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, Shuman M.Gene expression and angiotropism in primary CNS lymphoma.Blood 2006 May 1;107(9):3716
  16418334
• Aghi M, Gaviani P, Henson JW, Batchelor TT, Louis DN, Barker FG.Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma.Clin Cancer Res 2005 Dec 15;11(24 Pt 1):8600-5.
  16361543
• Batchelor T.Neuro-oncology update: 2005.Curr Opin Neurol 2005 Dec;18(6):631.
  16280672
• Mrugala MM, Batchelor TT, Plotkin SR.Peripheral and cranial nerve sheath tumors.Curr Opin Neurol 2005 Oct;18(5):604-10.
  16155448
• Fitzsimmons A, Upchurch K, Batchelor T.Clinical features and diagnosis of primary central nervous system lymphoma.Hematol Oncol Clin North Am 2005 Aug;19(4):689-703, vii.
  16083830
• Shih HA, Betensky RA, Dorfman MV, Louis DN, Loeffler JS, Batchelor TT.Genetic analyses for predictors of radiation response in glioblastoma.Int J Radiat Oncol Biol Phys 2005 Nov 1;63(3):704-10.
  15978739
• Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O'Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F,.Report of an
  15955902
• Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, Nabors LB, Chon B, Batchelor TT.Treatment of relapsed central nervous system lymphoma with high-dose methotrexate.Clin Cancer Res 2004 Sep 1;10(17):5643-6.
  15355887
• Batchelor TT, Betensky RA, Esposito JM, Pham LD, Dorfman MV, Piscatelli N, Jhung S, Rhee D, Louis DN.Age-dependent prognostic effects of genetic alterations in glioblastoma.Clin Cancer Res 2004 Jan 1;10(1 Pt 1):228-33.
  14734474
• Batchelor T, Carson K, O'Neill A, Grossman SA, Alavi J, New P, Hochberg F, Priet R.Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.J Clin Oncol 2003 Mar 15;21(6):1044-9.
  12637469
• Braaten KM, Betensky RA, de Leval L, Okada Y, Hochberg FH, Louis DN, Harris NL, Batchelor TT.BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma.Clin Cancer Res 2003 Mar;9(3):1063-9.
  12631608